HONG KONG, Jan 9, 2025 - (ACN Newswire) – The trading of TCE (T Cell Engager) bispecific antibodies remains hot, and multinational pharmaceutical companies (MNCs) are still placing orders frantically.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback